Radio-frequency Ablation of Solitary Adrenal Gland Metastasis From Renal Cell Carcinoma

Mouracadé, Pascal; Dettloff, H.; Schneider, Marc P.; Debras, Bertrand; Jung, Jean

doi:10.1016/j.urology.2009.06.058

Cited by 20 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the growing availability of percutaneous image-guided ablative technology and the development of expertise in treating both primary tumors and metastases in different viscera and regions within the body, both technical success and primary efficacy have been demonstrated in the use of magnetic resonance imaging-directed laser ablation, cryoablation, radiofrequency ablation, and microwave ablation of RCC metastases involving the adrenal gland, 46,47 the appendicular and axial skeleton, 48,49 and the lungs. [50][51][52] Therefore, particularly in patients who have low-volume metastatic disease who may not be surgical candidates, percutaneous thermal ablation appears to be a reasonable approach to consider.…”

Section: Percutaneous Thermal Ablationmentioning

confidence: 99%

Role of metastasis‐directed treatment in kidney cancer

Psutka

Master

2018

Cancer

View full text Add to dashboard Cite

Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive with systemic therapy alone. Definitive treatment of the metastatic deposit remains the sole potentially curative option and is a cornerstone of mRCC therapy, offering potential for both local control and palliation of tumor-related symptoms. In this review, the evidence supporting the definitive treatment of mRCC is examined and summarized, including the use of surgical metastasectomy, thermal ablation, radiotherapy, and other minimally invasive options. Multimodal approaches, including the combination of metastasectomy with novel systemic agents, are discussed. Finally, the authors review considerations for patient selection for this type of therapy and summarize available risk-stratification tools that may help guide shared decision making.

show abstract

Section: Percutaneous Thermal Ablationmentioning

confidence: 99%

Role of metastasis‐directed treatment in kidney cancer

Psutka

Master

2018

Cancer

View full text Add to dashboard Cite

show abstract

“…Over the last decade, there have been several reports of patients with unresectable adrenal metastases or poor operative risk treated with radiofrequency ablation without major complications and acceptable local control [97][98][99]. One of the largest studies reported the successful treatment of 11 adrenal metastases, six isolated to the adrenal gland, successfully controlled with chemotherapy, radiation therapy, and/or surgical resection.…”

Section: Radiofrequency Ablationmentioning

confidence: 99%

Surgical management of adrenal metastases

Sancho

Triponez

Montet

et al. 2011

Langenbecks Arch Surg

View full text Add to dashboard Cite

A patient with suspected adrenal metastasis should be considered a candidate for adrenalectomy when: (a) control of extra-adrenal disease can be accomplished, (b) metastasis is isolated to the adrenal gland(s), (c) adrenal imaging is highly suggestive of metastasis or the patient has a biopsy-proven adrenal malignancy, (d) metastasis is confined to the adrenal gland as assessed by a recent imaging study, and (e) the patient's performance status warrants an aggressive approach. In properly selected patients, laparoscopic (or retroperitoneoscopic) adrenalectomy is a feasible and safe option.

show abstract

“…In addition, many studies have reported that RFA may achieve 77–80% of local tumour control in AMs originated from lung or kidney [15–18]. However, there are few studies focus on RFA for the AMs originated from HCC.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous radiofrequency ablation of adrenal metastases from hepatocellular carcinoma: a single-center experience

et al. 2019

View full text Add to dashboard Cite

Background The prognosis of adrenal metastases (AM) from hepatocellular carcinoma (HCC) with surgical contraindication was poor. This study evaluated the feasibility, safety and treatment efficacy of percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) for the local treatment of AM originated from HCC. Methods A retrospective study was carried out on 22 patients (21 male and 1 female, mean age, 53.0 ± 13.0 years) who had single AM (mean diameter, 4.0 ± 1.8 cm, range, 1.7–8.0 cm) originated from HCC and received US-guided percutaneous RFA at our institution. The diagnosis was established on typical radiologic findings. The primary technical success was defined as the tumour being completely ablated in the first RFA session. The secondary technical success was defined as tumour residual left from the first ablation was completely ablated by a second ablation session. Local tumour progression (LTP) and overall survival (OS) were estimated by using Kaplan-Meier analysis. Results A total of 25 ablation sessions were performed. The primary technical success and the secondary technical success were 77.3% (17 of 22) and 86.4% (19 of 22), respectively, with the major complication rate at 4.5% (1 of 22). The median follow-up period after RFA was 10 months (3–55 months). During the follow-up period, five patients were detected LTP. The LTP at 3, 6, and 12 months were 15.8, 26.3, and 26.3%, respectively. Nine patients died of distant extra-adrenal metastases and another five of liver failure due to HCC. The OS at 6, 12, 24 months after RFA for AM were at 79.7, 52.6, and 32.9%, respectively. Conclusion Percutaneous US-guided RFA in the treatment of AM originated from HCC is feasible, safe and effective.

show abstract

Radio-frequency Ablation of Solitary Adrenal Gland Metastasis From Renal Cell Carcinoma

Cited by 20 publications

References 9 publications

Role of metastasis‐directed treatment in kidney cancer

Role of metastasis‐directed treatment in kidney cancer

Surgical management of adrenal metastases

Percutaneous radiofrequency ablation of adrenal metastases from hepatocellular carcinoma: a single-center experience

Contact Info

Product

Resources

About